199 related articles for article (PubMed ID: 38176304)
1. New insights into HER2-low breast cancer brain metastasis: A retrospective analysis.
Xu H; Wang Y; Li L; Han Y; Wu Y; Sa Q; Xu B; Wang J
Breast; 2024 Feb; 73():103669. PubMed ID: 38176304
[TBL] [Abstract][Full Text] [Related]
2. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
3. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer.
Qiao W; Guo W; Liu Q; Guo X; Deng M
Ann Diagn Pathol; 2023 Jun; 64():152125. PubMed ID: 36822053
[TBL] [Abstract][Full Text] [Related]
4. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases.
Hulsbergen AFC; Lamba N; Claes A; Kavouridis VK; Lin NU; Smith TR; Verhoeff JJC; Broekman MLD
World Neurosurg; 2019 Aug; 128():e157-e164. PubMed ID: 31035019
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development.
Saraf A; Grubb CS; Hwang ME; Tai CH; Wu CC; Jani A; Lapa ME; Andrews JIS; Vanderkelen S; Isaacson SR; Sonabend AM; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Cheng SK; Connolly EP; Wang TJC
J Neurooncol; 2017 Sep; 134(2):453-463. PubMed ID: 28674973
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
[TBL] [Abstract][Full Text] [Related]
9. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
Almstedt K; Heimes AS; Kappenberg F; Battista MJ; Lehr HA; Krajnak S; Lebrecht A; Gehrmann M; Stewen K; Brenner W; Weikel W; Rahnenführer J; Hengstler JG; Hasenburg A; Schmidt M
Eur J Cancer; 2022 Sep; 173():10-19. PubMed ID: 35839597
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
[TBL] [Abstract][Full Text] [Related]
14. Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract][Full Text] [Related]
15. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Van Swearingen AED; Siegel MB; Deal AM; Sambade MJ; Hoyle A; Hayes DN; Jo H; Little P; Dees EC; Muss H; Jolly T; Zagar TM; Patel N; Miller CR; Parker JS; Smith JK; Fisher J; Shah N; Nabell L; Nanda R; Dillon P; Abramson V; Carey LA; Anders CK
Breast Cancer Res Treat; 2018 Oct; 171(3):637-648. PubMed ID: 29938395
[TBL] [Abstract][Full Text] [Related]
16. Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis.
Chen YR; Xu ZX; Jiang LX; Dong ZW; Yu PF; Zhang Z; Gu GL
World J Clin Oncol; 2023 Nov; 14(11):445-458. PubMed ID: 38059189
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases.
Mills MN; Thawani C; Figura NB; Oliver DE; Soyano AE; Etame A; Robinson TJ; Liu JK; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Yu HM; Ahmed KA
J Neurooncol; 2021 May; 152(3):591-601. PubMed ID: 33742358
[TBL] [Abstract][Full Text] [Related]
18. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
Li JJ; Yu Y; Ge J
Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
[TBL] [Abstract][Full Text] [Related]
19. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
Shi Q; Yu J; Liu D; Ren F; Wu J; Shen K
BMC Cancer; 2023 Feb; 23(1):173. PubMed ID: 36810001
[TBL] [Abstract][Full Text] [Related]
20. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
